Children's Medical Center Corporation

Other

Harvard College

Nuchem Pharmaceuticals Inc.

Ion Pharmaceuticals, Inc.

John J Clifford

Adel M Moussa

Jose Alberto Halperin

Ying-Duo Gao

Minghua Sun

Yesh P Sachdeva

Carlo Brugnara

Richard John Lombardy

Reem M Haidar

Eugene W Kelleher

Heather N Taft

Emile M Bellott

Rudolf Fluckiger

Mark Froimowitz

Emile M Bellot, Jr

Falguni M Kher

Michael H Zeldin

The invention is a drilling device for providing a conically shaped cavity in materials primarily used for anchoring systems. The drilling device is comprised of a solid shank for attachment to a drill, a reverse thread section, and a cutting head. The cutting head includes a cutting tip, clean out flutes, extendable cutting blades mounted within an internal chamber of cutting head body, and means for extending the cutting blades. The extendable cutting blades project from the cutting head body radially when the reverse thread section is driven into the internal chamber of the cutting head. The reverse thread section interacts with the means for extending the cutting blades. This may include a pair of cams that are spring biased outwardly. The cams push against the backsides of the extendable cutting blades for driving them from the cutting head body when the drill device is counter rotated. The extendable blades cut a conical cavity at the distal end of a bore hole made by the cutting tip of the cutting head. After the conical cavity is produced, the drilling device is then clockwise rotated to cause the reverse threaded section being at its most distal position to return to its initial position. Biased springs mounted on the outer part of the body push the cutting blades into the body so that the drilling device can be removed from the bore hole.

Drilling device with undercutting

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease

The present invention provides substituted 3,3-diphenyl indole compounds, as well as analogues thereof, which are specific potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation

The present invention provides substituted 11-phenyl-dibenzazepine compounds that are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P, the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Growing community of inventors

Bedford, MA, United States of America

John J Clifford